Impact of COVID-19, initiatives, funding, major agreements and recent developments

Dublin, December 30, 2021 (GLOBE NEWSWIRE) – The “Global Liquid Biopsy Market by Circulating Biomarker, Product, Application, End User, Clinical Application, Cancer Types, Sample Type, Regional and Country Analysis – Impact of COVID-19, Initiatives, Funding, Major Agreements, and Recent Developments – Forecast for 2028 “ the report was added to offer.

The global liquid biopsy market is expected to reach $ 9.53 billion by 2028.

The advantages of liquid biopsy over solid tumor biopsy, the increasing prevalence of cancer, the increasing preference for non-invasive procedures, the increasing public and private funding to support research activities in the field of liquid biopsy and Supportive government initiatives, are some of the factors that are expected to propel the growth of the liquid biopsy market in the coming years.

Some of the key factors inhibiting the growth of the liquid biopsy market include challenges of clinical utility, lack of sensitivity and specificity of liquid biopsy tests, and an unclear reimbursement and regulatory scenario.

Impact of COVID-19

The COVID-19 outbreak has become a global stress test. As the number of people infected with the virus continues to rise around the world, uncertainties about global economic growth are increasing. The COVID-19 disease has infected an estimated 243 million people worldwide. Worldwide, the death toll has reached 4,937,666 according to the latest statistics from Worldometers (as of October 21, 2021). The number continues to grow and the duration of the pandemic is still difficult to predict.

The reactions to the COVID-19 pandemic and its effects on societies and economies around the world cannot be underestimated. The global COVID-19 pandemic has limited the growth rate of the liquid biopsy market to some extent during the period 2020-2021. However, many countries have taken strict measures to combat the coronavirus, such as a mass vaccination program, social distancing, the use of masks, etc. Hence, we would expect physicians / surgeons to see an increase in the influx of patients thus driving the liquid biopsy market growth.

Recent developments

  • In July 2021, Biocept, Inc. was granted a South Korean patent for its Primer-Switch technology, which detects rare mutations in circulating tumor DNA (ctDNA) using real-time PCR and testing methods. associated analysis.

  • In April 2021, Bio-Techne Corporation completed the acquisition of Asuragen, Inc.

  • In March 2021, Lucence announced a partnership with Waseda University in Japan to develop a new high-speed liquid biopsy laser imaging platform for the early detection of cancer.

  • In February 2021, Guardant Health, Inc. announced the availability of Guardant Reveal, the first blood-only liquid biopsy test for the detection of residual and recurrent disease from a simple blood test.

  • In August 2020, Freenome announced an oversubscribed US $ 270 million Series C funding, bringing the company’s total funding to more than US $ 500 million since the launch of the company.

  • On May 26, 2020, NeoGenomics, Inc. announced that it had formed a strategic collaboration with Inivata to commercialize the InVisionFirst-Lung liquid biopsy test in the United States.

  • In November 2019, Lucence Diagnostics Pte Ltd, a Singapore-based genomic medicine company, raised US $ 20 million in Series A funding.

  • In June 2019, Saga Diagnostics, a company based in Lund, Sweden, raised US $ 4.1 million in a funding round from Hadean Ventures.

Companies mentioned

  • Personal genome diagnosis

  • Guardant Santé, Inc.

  • Pathway Genomics (now OME CARE)

  • RainDance Technologies (acquired by Bio-Rad Laboratories, Inc.)

  • Cardiff Oncology (formerly Trovagene, Inc.)

  • LungLife AI (formerly Cynvenio Biosystems, Inc.)

  • Biocept, Inc.

  • ANGLE plc

  • MDxHealth

  • Biolidics Limited (formerly Clearbridge Biomedics Pte Ltd)

  • Exosome Diagnostics, Inc. (acquired by Bio-Techne Corporation)

  • Medicine Foundation, Inc

  • Roche Diagnostics (subsidiary of F. Hoffmann-La Roche AG)

  • Genomic Health (now part of Exact Sciences Corp)

  • Myriad Genetics, Inc

  • Thermo Fisher Scientific, Inc


  • Bio-Rad Laboratories, Inc

  • Menarini-Silicium Biosystems

  • Grail

  • NeoGenomics, Inc.

  • DiaCarta, Inc.

  • OncoCell MDx (now Immunis.AI)

  • C2i Genomics

  • Biodesix

  • Freenome

  • Inivata

  • CellMax Lifespan

  • Rarecyte Inc.

  • Diagnosis of the saga

  • Thrive Early Detection Corp. (acquired by Exact Sciences Corp.)

  • Lucence Diagnostics Pte Ltd

  • Karius, Inc.

  • Clinical Genomics Technologies Pty Ltd (CG)

  • Elypta

For more information on this report, visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Comments are closed.